Aspen Neuroscience, Inc. Common Stock (ASPE) Stock AnalysisASPEAspen Neuroscience, Inc. Common Stock

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.

Aspen Technology is not a good buy right now due to its recent acquisition by Emerson Electric, which has led to its shares ceasing to trade on NASDAQ. The stock will no longer be available for investment, making it impossible to buy. Additionally, the company has a low net margin of 6.70% and a return on equity (ROE) of only 0.05%, indicating weak profitability. The significant insider and hedge fund activity is overshadowed by the fact that the stock will soon be delisted from major exchanges, presenting a major risk for any potential investors.